Neue Behandlungsoptionen mit GnRH-Antagonisten bei Endometriose und Uterus myomatosus

Literatur Burgus R, Butcher M, Amoss M, Ling N, Monahan M, Rivier J, Fellows R, Vale W, Guillemin R (1972) Primary structure of the ovine hypothalamicluteinizing hormone-releasing factor (LRF) (LH-hypothalamus-LRF-gas chromatography-mass spectrometry-decapeptide-Edman degradation). Proc Natl Acad Sci U S A 69(1):278–282 Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV (1971) Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 43(6):1334–1339 Knobil E (1981) Discussion to “the neuroendocrine control of the menstrual cycle”. Recent Prog Horm Res 37:703–707 Koch Y, Baram T, Hazum E, Fridkin M (1977) Resistance to enzymic degradation of LH-RH analogues possessing increased biological activity. Biochem Biophys Res Commun 74(2):488–491 Reissmann T, Felberbaum R, Diedrich K (1995) Development and applications of luteinizinhormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 10:1974–1981 Klijn JG (1992) LH-RH agonists in the treatment of metastatic breast cancer: ten years’ experience. Recent Results Cancer Res 124:75–90 Lemay A, Maheux R, Faure N, Jean C, Fazekas AT (1984) Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41(6):863–871 Surrey ES (1999) Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group. Fertil Steril 71(3):420–424 Felberbaum RE, Reissmann T, Küpker W et al (1995) Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol 61:151–155 Griesinger G, Finas D, Alisch A, Roiha K, Schultze-Mosgau A, Schröder AK, Dafopoulos K, Diedrich K, Felberbaum R (2004) FSH time-concentration profiles before and after administration of 0.25 mg cetrorelix in the gnRH-antagonist multiple-dose protocol for ovarian hyperstimulation. J Assist Reprod Genet 21(7):279–282 Itskovitz-Eldor J, Kol S, Mannaerts B (2000) Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Hum Reprod 15:1965–1968 Barbieri RL (1998) Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment. J Reprod Med 43(3 Suppl):287–292 Pellicer A, Albert C, Garrido N et al (2000) The pathophysiology of endometriosis–associated infertility: follicular environment and embryo quality. J Reprod Fertil Suppl 55:109–119 Küpker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K (2002) Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 5(1):12–16 Buttram VC, Reiter RC (1981) Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 36:433–445 Holzmann C, Küpker W, Rommel B, Helmke B, Bullerdiek J (2020) Reasons to reconsider risk associated with power morcellation of uterine fibroids. In Vivo 34(1):1–9 Vitale SG, Ferrero S, Caruso S, Barra F, Marín-Buck A, Vilos GA, Vitagliano A, Török P, Ciebiera M, Cianci A (2020) Ulipristal acetate before hysteroscopic myomectomy: a systematic review. Obstet Gynecol Surv 75(2):127–135 Felberbaum RE, Germer U, Ludwig M, Riethmüller-Winzen H, Heise S, Buttge I, Bauer O, Reissmann T, Engel J, Diedrich K (1998) Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod 13(6):1660–1668 Felberbaum RE, Küpker W, Krapp M, Gehl B, Ludwig M, Diedrich K (2001) Preoperative reduction of uterine fibroids in only 16 days by administration of agonadotrophin-releasing hormone antagonist (Cetrotide). Reprod Biomed Online 3(1):14–18 De B, Plattner JJ, Bush EN, Jae HS, Diaz G, Johnson ES, Perun TJ (1989) LH-RH antagonists: design and synthesis of a novel series of peptidomimetics. J Med Chem 32(9):2036–2038 Cho N, Harada M, Imaeda T, Imada T, Matsumoto H, Hayase Y, Sasaki S, Furuya S, Suzuki N, Okubo S, Ogi K, Endo S, Onda H, Fujino M (1998) Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J Med Chem 41(22):4190–4195 Wilcoxen KM, Zhu YF, Connors PJ, Saunders J, Gross TD, Gao Y, Reinhart GJ, Struthers RS, Chen C (2002) Synthesis and initial structure-activity relationships of a novel series of imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists. Bioorg Med Chem Lett 12(16):2179–2183 Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS (2008) Discovery of sodium R‑(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluortrifluoromethyl]benzyl)-4-methyl‑2,6‑dioxo‑3,6‑dihydro-2H-pyrimidin-1-yl]-1phenylethylamino}butyrate(elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem 51(23):7478–7485 Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K (2017) Treatment of endometriosis-associated pain with Elagolix, an oral GnRH antagonist. N Engl J Med 377(1):28–40 Taylor HS (2018) Use of Elagolix in Gynaecology. J Obstet Gynaecol Can 40(7):931–934 Shebley M, Polepally A, Nader A, Ng JW, Winzenborg I, Klein CE, Noerteraheuser P, Gibbs MA, Mostafa NM (2020) Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmakinetics 59:297–309 Lamb YN (2018) Elagolix: first global approval. Drugs 78(14):1501–1508 Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H (2019) Oral gonadotropin-releasinghormone antagonist relugolix compared with Leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 133(3):423–433 Osuga Y, Enya K, Kudou K, Hoshiai H (2019) Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril 112(5):922–929.e2 Pohl O, Marchand L, Bell D, Gotteland JP (2020) Effects of combined GnRH receptor antagonist Lingagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci 27(4):988–995 Shore ND, Saad F, Cookson MS et al (2020) Oral Relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382(23):2187–2196 Author information Authors and Affiliations Corresponding author Ethics declarations Interessenkonflikt W. Küpker, D. Plathow, J. Bullerdiek und R. Felberbaum geben an, dass kein Interessenkonflikt besteht. Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Additional information Redaktion B. Imthurn, Zürich O. Ortmann, Regensburg C. Tempfer, Herne Teile dieses Beitrags wurden bereits publiziert in Küpker, W., Felberbaum, R. Neue Behandlungsmöglichkeiten der Endometriose mit GnRH-Antagonisten. Gynäkologe (2020). https://doi.org/10.1007/s00129-020-04633-z Rights and permissions About this article Cite this article Küpker, W., Plathow, D., Bullerdiek, J. et al. Neue Behandlungsoptionen mit GnRH-Antagonisten bei Endometriose und Uterus myomatosus. Gynäkologische Endokrinologie 18, 169–174 (2020). https://doi.org/10.1007/s10304-020-00329-8 Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s10304-020-00329-8